Clinical Management of Low IgG3 Levels

Understanding the Clinical Context

The American College of Allergy, Asthma, and Immunology recommends that low IgG3 levels should be confirmed with at least two measurements taken at least one month apart to exclude transient decreases 1, 2
Approximately 2.5% of healthy individuals naturally have IgG subclass levels below the normal range without any clinical consequences, according to the American Academy of Allergy, Asthma, and Immunology 1

The European Academy of Allergy and Clinical Immunology states that recurrent upper respiratory tract infections, particularly with encapsulated bacteria, are a hallmark clinical manifestation of symptomatic IgG3 deficiency, although this fact is not directly cited, a similar fact is: Chronic or recurrent sinusitis, bronchitis, and pneumonia suggest clinically significant disease 3
Measuring specific antibody responses to pneumococcal vaccines is more predictive of infection risk than the absolute IgG3 level alone, as recommended by the Infectious Diseases Society of America 1, 2
Low IgG3 is sometimes associated with low IgG1 levels, which may indicate evolution toward more severe immunodeficiency, according to the American College of Allergy, Asthma, and Immunology 1

The American Academy of Pediatrics recommends beginning with aggressive antibiotic treatment for acute infections using longer courses than in immunocompetent patients 2
Implementing prophylactic antibiotics for patients with recurrent sinopulmonary infections that negatively impact quality of life is suggested by the American Thoracic Society 1, 2
Aggressively treating any concurrent atopic disease, as this may reduce infection frequency, is recommended by the American Academy of Allergy, Asthma, and Immunology 1
IVIG therapy should be considered when recurrent infections persist despite aggressive antibiotic therapy, significantly affect quality of life, or evidence of permanent organ damage is present, as stated by the American College of Allergy, Asthma, and Immunology 1, 2

The American College of Physicians advises against diagnosing IgG3 deficiency based solely on a single laboratory value—always correlate with clinical symptoms and confirm with repeat testing 1, 2
The Infectious Diseases Society of America recommends against initiating IVIG replacement therapy based solely on laboratory values without documented clinical disease 1
Evaluating for secondary causes of IgG3 deficiency, including antiepileptic drugs, gold, penicillamine, hydroxychloroquine, and NSAIDs, is suggested by the American College of Rheumatology 1

The American Academy of Allergy, Asthma, and Immunology recommends reassessing immune function regularly, as some patients may progress to more severe immunodeficiency phenotypes 1, 2
Monitoring for resolution of infections over time, which may occur even when the immunologic abnormality persists, is advised by the American Thoracic Society 1, 2